Pharmaceuticals News and Research

RSS

Additional data from Tokai’s galeterone Phase 1 study on CRPC

Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that additional data from a Phase 1 safety and proof-of-concept study evaluating lead candidate, galeterone, in patients with castration-resistant prostate cancer (CRPC) will be highlighted in a poster presentation titled, "Phase I clinical trial of galeterone, a multifunctional anti-androgen and CYP17 inhibitor in castration resistant prostate cancer," abstract number 4665, on Sunday, June 3, 2012, 8:00 a.m. to 12:00 p.m. at the 2012 Annual Meeting of the American Society of Clinical Oncology.

18 May 2012

Pharmos completes levotofisopam phase 2a trial on hyperuricemia, gout

Pharmos Corporation announced that it has successfully completed a proof-of-concept clinical trial using its compound levotofisopam (S-tofisopam) to treat patients with hyperuricemia and gout.

18 May 2012

Mylan receives final FDA approval for Clopidogrel Tablets ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clopidogrel Tablets USP, 75 mg and 300 mg.

18 May 2012

Spectrum initiates ZEVALIN and MGd Phase 2 combination study in NHL

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the initiation of a Phase 2 study evaluating ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use + rituximab in combination with motexafin gadolinium (MGd) in patients with rituximab-refractory low-grade or follicular B-cell non-Hodgkin's lymphoma.

18 May 2012

Multiple companies receive FDA approval to sell generic Plavix

The U.S. Food and Drug Administration today approved generic versions of the blood thinning drug Plavix (clopidogrel bisulfate), which helps reduce the risk of heart attack and stroke by making it less likely that platelets in the blood will clump and form clots in the arteries.

18 May 2012

Inovio SynCon avian influenza vaccine demonstrates broad coverage

Inovio Pharmaceuticals, Inc. announced today that its SynCon avian influenza vaccine generated protective HAI titers against six different unmatched strains of H5N1 in a phase I clinical trial - a distinct clinical achievement on Inovio's path to develop universal influenza vaccines.

17 May 2012

Study reveals pathway that may help slow development of multiple myeloma

Researchers at NYU School of Medicine have identified a target for slowing the progression of multiple myeloma by using currently available drugs.

17 May 2012

Apigenin effective against human breast cancer

Apigenin, a natural substance found in grocery store produce aisles, shows promise as a non-toxic treatment for an aggressive form of human breast cancer, following a new study at the University of Missouri.

17 May 2012

ACE2 molecule now protects major organs in diabetic patients

ACE2, a molecule that has been shown to prevent damage in the heart, is now proving to be protective of the major organs that are often damaged in diabetic patients.

17 May 2012

Dako, VARI partner to license, manufacture and distribute cancer diagnostics

Van Andel Research Institute (VARI) and Dako, the Danish-based, worldwide supplier of cancer diagnostic tools today announce an agreement to license, manufacture and distribute cancer diagnostics utilizing the MET4 Antibody.

17 May 2012

Pfizer outlines vision for Systems-based Pharmaceutics

Leading pharmaceuticals company Pfizer outlined its vision for Systems-based Pharmaceutics, a revolutionary model-based approach linking drug process and product engineering to product quality and performance in the human body, at the recent Advanced Process Modelling Forum in London.

17 May 2012

Results from Boehringer Ingelheim’s LUX-Lung 3 Phase III trial on stage IIIB or IV NSCLC

Boehringer Ingelheim will present results from LUX-Lung 3, the company's pivotal Phase III clinical trial investigating afatinib in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation (EGFR M+), at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2012.

17 May 2012

Shengtai third quarter net sales decrease 4.52% to $39,803,608

Shengtai Pharmaceutical, Inc., a manufacturer and distributor in China of glucose and starch as pharmaceutical raw materials and other starch and glucose products, today reported financial results for the third quarter of fiscal 2012 ended March 31, 2012.

16 May 2012

First patient included in the phase II study of Amphinex® in head and neck cancer patients

PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the first patient has been included in the phase II study of Amphinex in combination with the cytotoxic agent bleomycin in head and neck cancer patients, called the ENHANCE study. The first patient was included at the National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Germany. NCT is a joint project of the German Cancer Research Center (DKFZ), Heidelberg University Hospital, Thoraxklinik Heidelberg and Deutsche Krebshilfe (German Cancer Aid).

16 May 2012

Codexis receives U.S. patent for enzymes utilized in HCV therapeutics

Codexis, Inc., a developer of cost-advantaged processes for the production of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced that the United States Patent and Trademark Office (USPTO) has granted Codexis' patent covering the biocatalysts and biocatalytic processes used to make key pharmaceutical intermediates in the synthesis of leading hepatitis-C therapeutics.

16 May 2012

U.N. Office on Drugs, Interpol better equipped than WHO to combat counterfeit drug trade

"The worldwide counterfeit drug market is huge and growing," Tim Mackey and Brian Liang of the Institute of Health Law Studies at the California Western School of Law and Thomas Kubic of the Pharmaceutical Security Institute write in a Foreign Policy opinion piece, noting such "drugs occupy a wide spectrum of medications, and their quality is suspect; they can be mislabeled, tainted, adulterated, ineffective, or, in the worst cases, all of the above."

16 May 2012

Sorin receives PMDA authorization to market MEMO 3D ring

Sorin Group, a global medical device company and a leader in the treatment of cardiovascular diseases, announces that it received authorization from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to market its MEMO 3D Semi-Rigid Annuloplasty Ring.

16 May 2012

Viewpoints: Calif. health, welfare programs struggle under budget cuts; Protecting children from diabetes threat

Gov. Jerry Brown and the Democratic-controlled Legislature passed a budget last year that was built on a rickety foundation of false hopes. If that wasn't apparent at the time, it is now that the budget deficit has ballooned to $15.7 billion, up from Brown's $9.2 billion estimate from only four months ago. ... Brown offered several solutions on Monday. Health and welfare programs for the poor would bear 30 percent of the cuts, including $880 million from the main welfare program, CalWORKs, through a variety of reductions.

16 May 2012

Nile reports net operating loss of $0.8M for first quarter 2012

Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced its first quarter financial results for 2012.

16 May 2012

Combination of vaccine and letrozole effectively improves survival from breast cancer

A vaccine that targets cancer cells in combination with the drug letrozole, a standard hormonal therapy against breast cancer, significantly increased survival when tested in mice, a team of UC Davis investigators has found.

16 May 2012